138 related articles for article (PubMed ID: 1633301)
1. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Meneghetti CM; LeMaistre CF
Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
[No Abstract] [Full Text] [Related]
2. The role of recombinant interleukin-2 in therapy for hematologic malignancies.
Dutcher JP; Wiernik PH
Semin Oncol; 1993 Dec; 20(6 Suppl 9):33-40. PubMed ID: 8284690
[No Abstract] [Full Text] [Related]
3. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
5. Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease.
Murphy JR; Lakkis FG; vanderSpek JC; Anderson P; Strom TB
Targeted Diagn Ther; 1992; 7():365-82. PubMed ID: 1633299
[No Abstract] [Full Text] [Related]
6. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
[No Abstract] [Full Text] [Related]
7. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
Bunn PA
Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
[No Abstract] [Full Text] [Related]
8. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
Kazin R; Bujanauskas P; Vonderheid EC
J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
[No Abstract] [Full Text] [Related]
9. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2).
Cohen R; Jaffe ES; Stetler-Stevenson MA; Sausville EA; DeNigris EC; Woodworth T; Foss FM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):229-33. PubMed ID: 7834123
[TBL] [Abstract][Full Text] [Related]
10. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
[TBL] [Abstract][Full Text] [Related]
11. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
Foss FM
Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of non-Hodgkin lymphoma: interleukin-2 fusion toxin. A review of selected abstracts from the 2004 Annual Meeting of the American Society of Hematology. December 4-7, 2004, San Diego, California.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 2):1-5; discussion 6-7. PubMed ID: 21434476
[No Abstract] [Full Text] [Related]
13. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
[TBL] [Abstract][Full Text] [Related]
14. New advances in the management of cutaneous T-cell lymphoma.
Young SK
Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
[No Abstract] [Full Text] [Related]
15. Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis.
Miller DD; Bach RG; Tio FO; Bailey SR; Waters CA; Woodworth TG; Nichols JC; Paige SB; Farrar M
Atherosclerosis; 1996 Sep; 126(1):1-14. PubMed ID: 8879429
[TBL] [Abstract][Full Text] [Related]
16. Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443.
Hullett DA; Landry AS; Eckoff DE; Nichols JC; Eugui EM; Allison AC; Sollinger HW
Transpl Int; 1992; 5 Suppl 1():S487-9. PubMed ID: 14621855
[TBL] [Abstract][Full Text] [Related]
17. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
[No Abstract] [Full Text] [Related]
18. Denileukin diftitox and vision loss.
Ruddle JB; Prince HM
Leuk Lymphoma; 2007 Apr; 48(4):655-6. PubMed ID: 17454621
[No Abstract] [Full Text] [Related]
19. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
[TBL] [Abstract][Full Text] [Related]
20. Optimizing denileukin diftitox (Ontak) therapy.
Duvic M; Talpur R
Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]